Yazar "Erten, Şükran" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Can anticarbamylated protein antibodies be used to support the diagnosis of systemic lupus erythematosus?
    (Future Medicine Ltd, 2021) Özdemir, Bahar; Erden, Abdulsamet; Erten, Şükran; Yeşil, Turan Hilmi; Alışık, Murat; Küçükşahin, Orhan
    Aim: Autoantibody development plays an important role in the pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In this study, we aimed to determine the diagnostic value of anticarbamylated protein antibody (anti-CarP) antibody in SLE and RA patients and its relationship with disease prognosis. Material & method: Fifty-seven SLE patients (F/M 50/7; median age 40.9 +/- 13.7; median disease duration 2 years) who met the 2012 SLICC SLE diagnostic criteria were included in the study. A total of 46 RA patients selected according to the 2010 ACR/EULAR diagnostic criteria (F/M 38/8; median age 54.2 +/- 12.4; median disease duration 2 years) were included. A total of 30 healthy individuals were selected as the control group. The anti-CarP antibody was studied by using human anticarbamylated protein antibody ELISA Kit (SunRedBio, Shanghai, China). Results: Anti-CarP antibody positivity was found to be 17.4% in RA patients (p < 0.001), 54.4% in SLE patients (p < 0.001) and 3.3% in the healthy control group. The anti-CarP antibody was determined to predict SLE patients with 54.4% sensitivity and 96.7% specificity compared with the healthy control group (area under the curve: 0.755; p < 0.001). Conclusion: Anti-CarP antibody positivity was significantly higher in the SLE patients compared with the healthy control and RA group. It has significant sensitivity and specificity in both SLE and RA patients compared with the healthy controls.
  • Küçük Resim Yok
    Öğe
    Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?
    (Bentham Science Publishers, 2024) Kor, Ahmet; Orhan, Kevser; Maraş, Yüksel; Oğuz, Esra Fırat; Unan, Mehtap Kalçık; Dilek, Gamze; Erten, Şükran
    Aim: The clinical symptoms and laboratory markers of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) can be very similar, so making a differential diagnosis between these two diseases is often difficult. Serological parameters to be used in differential diagnosis can guide the clinician. This study aimed to investigate the usability of 14-3-3? (eta) protein as a biomarker in the differential diagnosis of PsA and RA, and the relationships between eta protein and disease activity scores and joint erosions in PsA and RA. Methods: 54 PsA patients, 53 RA patients, and 56 healthy individuals were included in this study. The ELISA (Enzyme-Linked ImunoSorbent Assay) kit was used as a quantitative sandwich enzyme immunoassay technique to detect human eta protein levels. Receiver-operating Characteristic (ROC) curves analysis was used to determine the sensitivity and specificity of the eta protein. Results: Eta protein levels were found to be significantly higher in the RA group than in the PsA [B:-0.341, OR (95% CI): 0.711 (0.556-0.909), p: 0.007] and control [B:-0.225, OR (95% CI): 0.798 (0.641-0.995), p: 0.045] groups. Eta protein median values were significantly higher in patients with joint erosion than in those without [?= 0.151, OR (95% CI): 1.163 (1.003-1.349), p: 0.046]. Conclusion: Eta protein levels are higher in the serum of RA patients than PsA and are associated with joint erosion. Eta protein may be a potential biomarker in the differential diagnosis of RA and PsA. It may represent a possible therapeutic step in the pathophysiological pathways in the development of joint erosion. © 2024 Bentham Science Publishers.